10/6/2020

Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020

Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020

ORION CORPORATION PRESS RELEASE 6 OCTOBER 2020 at 15.00 EEST             
         
Orion publishes Interim Report for January-September 2020 on Wednesday 21 October 2020

Orion will publish Interim Report for January-September 2020 on Wednesday, 21 October 2020 approximately at 12.00 noon EEST. The report and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media will be held on Wednesday, 21 October 2020 at 13.30 EEST. The event will be held only online and by conference call.

A link to the live webcast will be available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.

To participate the conference call, please dial:

Finland: +358 9 817 103 10
Sweden: +46 8 566 426 51
UK: +44 333 300 0804
USA:  +1 631 913 1422

PIN: 15529281#

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

                                                                                                                                   
Contact person:
Tuukka Hirvonen, Investor Relations, Orion Corporation
tel. +358 10 426 2721

Publisher:
Orion Corporation
Communications
Orionintie 1A, FI-02200 Espoo, Finland
www.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients. The company is continuously developing new drugs and treatment methods. The core therapy areas of Orion's pharmaceutical R&D are central nervous system (CNS) disorders, oncology, Finnish heritage rare diseases and respiratory diseases for which Orion develops inhaled Easyhaler® pulmonary drugs. Orion's net sales in 2019 amounted to EUR 1,051 million and the company had about 3,300 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.